

Name: Ching-Lung LAI

Academic Qualifications: MBBS(Honours)(HKU)(HK), 1970; MD(HKU)(HK), 1994

Present academic position: Simon K Y Lee Professor in Gastroenterology (2011-present),
Chair of Medicine & Hepatology (2003-present), Department of Medicine,
The University of Hong Kong (HKU), Pokfulam, Hong Kong

Previous academic position: Sir David Todd Professor (2001-2003), Department of Medicine, The
University of Hong Kong (HKU), Pokfulam, Hong Kong

Present HA clinical position: Honorary Consultant Physician (1981-Present), Department of Medicine,
Queen Mary Hospital (QMH), 102 Pokfulam Road, Hong Kong

Address: Department of Medicine, Queen Mary Hospital, 102 Pokfulam Road,
Pokfulam, Hong Kong

Year of GCP training completed: 2011

Major Research Interests:

- The natural history of chronic hepatitis B in the Chinese, especially with reference to ccc HBV DNA.
- The treatment of chronic hepatitis B.
- The treatment of hepatocellular carcinoma.

Publications

- Peer-reviewed Articles > 530 Books = 4, Book Chapters and Monographs = 20, Abstracts > 315.
- Selected book: Co-editor with Locarnini S, “Hepatitis B Virus”, Human Virus Guides, International Medical Press, 1st Ed, February 2003 and 2nd Ed, October 2008.
- Ranked ISI-Thompson top 1% scientist in ‘Clinical Medicine’ and ‘All Fields’

Representative Publications

1. **Lai CL**, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, Huang FY, Lee B, Cullaro G, Chong CK, Wu R, Cheng C, Yuen J, Ngai V, Yuen MF. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. *J Hepatol.* 2017 Feb;66(2):275-281.
2. Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, Ferrari C, Given BD, Hamilton J, Kanner SB, **Lai CL**, Lau JYN, Schlupe T, Xu Z, Lanford RE, Lewis DL. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. *Sci Transl Med.* 2017 Sep 27;9(409).
3. **Lai CL**, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, Huang FY, Lee B, Cullaro G, Chong CK, Wu R, Cheng C, Yuen J, Ngai V, Yuen MF. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. *J Hepatol.* 2017 Feb;66(2):275-281.
4. Fung J, Seto WK, **Lai CL**, Yuen J, Wong DK, Yuen MF. Corrigendum to "Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy" [*J Hepatol* 2011;54:195-200]. *J Hepatol.* 2016 Jun;64(6):1460.
5. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, **Lai CL**, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. *N Engl J Med* 2015; 373:2599-607.
6. **Lai CL**, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Han KH, Yuen MF. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. *Gut* 2014; 63:996-1004.

7. Gane EJ, Deray G, Liaw YF, Lim SG, **Lai CL**, Rasenack J, Wang Y, Papatheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A. Telbivudine improves renal function in patients with chronic hepatitis B. *Gastroenterology* 2014; 146(1):138-146.e5.
8. **Lai CL**, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. *Hepatology* 2013;57:399-408.
9. Seto WK, Wong DK, Fung J, Huang FY, **Lai CL**, Yuen MF. Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. *Hepatology* 2013;58:923-31
10. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, **Lai CL**, Lo CM. Oral nucleoside/nucleotide analogues without hepatitis B immune globulin after liver transplantation for hepatitis B. *American Journal of Gastroenterology* 2013; 108:942-948.
11. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, **Lai CL**. Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. *American Journal of Gastroenterology* 2011; 106:1264-71.
12. **Lai CL**, Yuen MF. Chronic hepatitis B - new goals, new treatment. *New England Journal of Medicine* 2008; 359:2488-2491.
13. **Lai CL**, Gane E, Liaw YF, Hsu CW, Thongawat S, Wang YM, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. *New England Journal of Medicine* 2007; 357:2576-2588.
14. **Lai CL**, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. *Annals of Internal Medicine* 2007; 147:58-61.
15. **Lai CL**, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *New England Journal of Medicine* 2006; 354:1011-1020.

Other: Research-related Prizes and Awards

- Awarded the Bristol-Myers Squibb Unrestricted Biomedical Research Grant of US\$500,000 for 2001-2005 for distinction in Infectious Diseases in 2001.
- Awarded the Outstanding Researcher Award, The University of Hong Kong in 2004.
- Awarded the Outstanding Research Student Supervisor Award, The University of Hong Kong in 2006.